Integrated approach toward the discovery of glyco-biomarkers of inflammation-Related diseases

Annals of the New York Academy of Sciences

Volumn 1253, Issue 1, 2012, Pages 159-169

  Angata, Takashi ^a   Fujinawa, Reiko ^a   Kurimoto, Ayako ^a   Nakajima, Kazuki ^a   Kato, Masaki ^a   Takamatsu, Shinji ^a   Korekane, Hiroaki ^a   Gao, Cong Xiao ^a   Ohtsubo, Kazuaki ^a   Kitazume, Shinobu ^a   Taniguchi, Naoyuki ^a  

^a RIKEN   (Japan)

Author keywords

Alzheimer's disease; Cancer; Chronic inflammation; Chronic obstructive pulmonary disease; Glyco biomarker; Systems biology

Indexed keywords

ALPHA FETOPROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CD33 ANTIGEN; DUPAN 2; EPIDERMAL GROWTH FACTOR; FUCOSYLTRANSFERASE; GLYCAN; HEPATOCYTE NUCLEAR FACTOR 1BETA; SIALYL LEWIS X ANTIGEN; SURFACTANT PROTEIN D; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALZHEIMER DISEASE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; ENDOMETRIOSIS; FULMINANT HEPATIC FAILURE; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG FIBROSIS; METABOLIC SYNDROME X; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

EID: 84860231407     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06469.x     Document Type: Review

References (107)

1. Rifai, N., M.A. Gillette & S.A. Carr. 2006. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24: 971-983.
2. Sawyers, C.L. 2008. The cancer biomarker problem. Nature 452: 548-552.
3. Aoyagi, Y., Y. Tamura & T. Suda. 2011. History and recent progress in evaluation of the fucosylated alpha-fetoprotein fraction. J. Gastroenterol. Hepatol. 26: 615-616.
4. Taketa, K., Y. Endo, C. Sekiya, et al. 1993. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 53: 5419-5423.
5. Magnani, J.L., B. Nilsson, M. Brockhaus, et al. 1982. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J. Biol. Chem. 257: 14365-14369.
6. Safi, F., R. Roscher, R. Bittner, et al. 1987. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 2: 398-403.
7. Sawabu, N., Y. Takemori, D. Toya, et al. 1986. Factors affecting serum levels of CA 19-9 with special reference to benign hepatobiliary and pancreatic diseases. Gastroenterol. Jpn. 21: 491-498.
8. Szekanecz, E., Z. Sandor, P. Antal-Szalmas, et al. 2007. Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann. N.Y. Acad. Sci. 1108: 359-371.
9. Kawa, S., M. Tokoo, H. Oguchi, et al. 1994. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas 9: 692-697.
10. Mahvi, D.M., H.F. Seigler, W.C. Meyers, et al. 1988. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Pancreas 3: 488-493.
11. Kumamoto, K., C. Mitsuoka, M. Izawa, et al. 1998. Specific detection of sialyl Lewis X determinant carried on the mucin GlcNAcbeta1->6GalNAcalpha core structure as a tumor-associated antigen. Biochem. Biophys. Res. Commun. 247: 514-517.
12. De Graaf, T.W., M.E. Van der Stelt, M.G. Anbergen & W. van Dijk. 1993. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. J. Exp. Med. 177: 657-666.
13. van Dijk, W., E.C. Havenaar & E.C. Brinkman-van der Linden. 1995. Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Glycoconj. J. 12: 227-233.
14. Kjeldsen, T., H. Clausen, S. Hirohashi, et al. 1988. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 48: 2214-2220.
15. Nozawa, S., D. Aoki, M. Yajima, et al. 1992. CA54/61 as a marker for epithelial ovarian cancer. Cancer Res. 52: 1205-1209.
16. Hanisch, F.G., G. Uhlenbruck, C. Dienst, et al. 1985. Ca 125 and Ca 19-9: two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk. Eur. J. Biochem. 149: 323-330.
17. Halila, H., U.H. Stenman & M. Seppala. 1986. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 57: 1327-1329.
18. Daoud, E. & G. Bodor. 1991. CA-125 concentrations in malignant and nonmalignant disease. Clin. Chem. 37: 1968-1974.
19. Patton, P.E., C.S. Field, R.W. Harms & C.B. Coulam. 1986. CA-125 levels in endometriosis. Fertil. Steril. 45: 770-773.
20. Hinoda, Y., H. Kakiuchi, N. Nakagawa, et al. 1992. Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin-comparison of antigen MUSE11 with CA15-3. Gastroenterol. Jpn. 27: 390-395.
21. Ricci, A., S. Mariotta, E. Bronzetti, et al. 2009. Serum CA 15-3 is increased in pulmonary fibrosis. Sarcoidosis Vasc. Diffuse. Lung Dis. 26: 54-63.
22. Ludwig, J.A. & J.N. Weinstein. 2005. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5: 845-856.
23. Kannagi, R. 2009. List of tumor markers. J. Jpn. Med. Assoc. 138 (Special issue 1): S346-S349 (in Japanese).
24. Steinberg, W. 1990. The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol. 85: 350-355.
25. Arnold, J.N., R. Saldova, U.M. Hamid & P.M. Rudd. 2008. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8: 3284-3293.
26. Mantovani, A., P. Allavena, A. Sica & F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
27. Grivennikov, S.I., F.R. Greten & M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883-899.
28. Weinberg, R.A. 2006. The Biology of Cancer. Garland Science. New York.
29. Brockhausen, I. 2006. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 7: 599-604.
30. Hakomori, S. 2001. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491: 369-402.
31. Callewaert, N., H. Van Vlierberghe, A. Van Hecke, et al. 2004. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 10: 429-434.
32. Goldman, R., H.W. Ressom, R.S. Varghese, et al. 2009. Detection of hepatocellular carcinoma using glycomic analysis. Clin. Cancer Res. 15: 1808-1813.
33. Jacob, F., D.R. Goldstein, N.V. Bovin, et al. 2012. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array. Int. J. Cancer 130: 138-146.
34. Packer, N.H., C.W. von der Lieth, K.F. Aoki-Kinoshita, et al. 2008. Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 8: 8-20.
35. Ito, H., A. Kuno, H. Sawaki, et al. 2009. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J. Proteome Res. 8: 1358-1367.
36. Narimatsu, H., H. Sawaki, A. Kuno, et al. 2010. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 277: 95-105.
37. Taniguchi, N., A. Ekuni, J.H. Ko, et al. 2001. A glycomic approach to the identification and characterization of glycoprotein function in cells transfected with glycosyltransferase genes. Proteomics 1: 239-247.
38. Miyoshi, E., K. Moriwaki & T. Nakagawa. 2008. Biological function of fucosylation in cancer biology. J. Biochem. 143: 725-729.
39. Moriwaki, K. & E. Miyoshi. 2010. Fucosylation and gastrointestinal cancer. World J. Hepatol. 2: 151-161.
40. Nishihara, S., H. Narimatsu, H. Iwasaki, et al. 1994. Molecular genetic analysis of the human Lewis histo-blood group system. J. Biol. Chem. 269: 29271-29278.
41. Mollicone, R., A. Cailleau & R. Oriol. 1995. Molecular genetics of H, Se, Lewis and other fucosyltransferase genes. Transfus. Clin. Biol. 2: 235-242.
42. El-Serag, H.B. & K.L. Rudolph. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
43. Farazi, P.A. & R.A. DePinho. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6: 674-687.
44. Aoyagi, Y., Y. Suzuki, M. Isemura, et al. 1988. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61: 769-774.
45. Noda, K., E. Miyoshi, N. Uozumi, et al. 1998. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology 28: 944-952.
46. Noda, K., E. Miyoshi, J. Gu, et al. 2003. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res. 63: 6282-6289.
47. Moriwaki, K., K. Noda, T. Nakagawa, et al. 2007. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. Glycobiology 17: 1311-1320.
48. Nakagawa, T., N. Uozumi, M. Nakano, et al. 2006. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J. Biol. Chem. 281: 29797-29806.
49. Kuno, A., Y. Ikehara, Y. Tanaka, et al. 2011. Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. Clin. Chem. 57: 48-56.
50. Dwek, M.V., A. Jenks & A.J. Leathem. 2010. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin. Chim. Acta 411: 1935-1939.
51. Fukushima, K., T. Satoh, S. Baba & K. Yamashita. 2010. Alpha1, 2-fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 20: 452-460.
52. De Marzo, A.M., E.A. Platz, S. Sutcliffe, et al. 2007. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7: 256-269.
53. Radhakrishnan, P., V. Chachadi, M.F. Lin, et al. 2011. TNFalpha enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem. Biophys. Res. Commun. 409: 436-441.
54. Lauc, G., A. Essafi, J.E. Huffman, et al. 2010. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation. PLoS Genet. 6: e1001256.
55. Reiner, A.P., M.D. Gross, C.S. Carlson, et al. 2009. Common coding variants of the HNF1A gene are associated with multiple cardiovascular risk phenotypes in community-based samples of younger and older European-American adults: the Coronary Artery Risk Development in Young Adults Study and The Cardiovascular Health Study. Circ. Cardiovasc. Genet. 2: 244-254.
56. Voight, B.F., L.J. Scott, V. Steinthorsdottir, et al. 2010. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42: 579-589.
57. Okuyama, N., Y. Ide, M. Nakano, et al. 2006. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 118: 2803-2808.
58. Nakano, M., T. Nakagawa, T. Ito, et al. 2008. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int. J. Cancer 122: 2301-2309.
59. Narisada, M., S. Kawamoto, K. Kuwamoto, et al. 2008. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem. Biophys. Res. Commun. 377: 792-796.
60. Leu, J.I., M.A. Crissey, J.P. Leu, et al. 2001. Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol. Cell Biol. 21: 414-424.
61. Narimatsu, H., H. Iwasaki, F. Nakayama, et al. 1998. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 58: 512-518.
62. Narimatsu, H., H. Iwasaki, S. Nishihara, et al. 1996. Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Cancer Res. 56: 330-338.
63. Querfurth, H.W. & F.M. LaFerla. 2010. Alzheimer's disease. N. Engl. J. Med. 362: 329-344.
64. Klunk, W.E., H. Engler, A. Nordberg, et al. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55: 306-319.
65. Williams, R. 2011. Biomarkers: warning signs. Nature 475: S5-S7.
66. Buckholtz, N.S. 2011. Perspective: in search of biomarkers. Nature 475: S8.
67. Humpel, C. 2011. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 29: 26-32.
68. Blennow, K., H. Hampel, M. Weiner & H. Zetterberg. 2010. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6: 131-144.
69. Calhoun, M.E., P. Burgermeister, A.L. Phinney, et al. 1999. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U. S. A. 96: 14088-14093.
70. Nicoll, J.A., M. Yamada, J. Frackowiak, et al. 2004. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Aging 25: 589-597; discussion 603-604.
71. Fiala, M., P.T. Liu, A. Espinosa-Jeffrey, et al. 2007. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. U. S. A. 104: 12849-12854.
72. Taniguchi, N., E. Miyoshi, J.H. Ko, et al. 1999. Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim. Biophys. Acta 1455: 287-300.
73. Ferrara, C., P. Brunker, T. Suter, et al. 2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 93: 851-861.
74. Akasaka-Manya, K., H. Manya, Y. Sakurai, et al. 2010. Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease. Glycobiology 20: 99-106.
75. Saez-Valero, J., G. Sberna, C.A. McLean, et al. 1997. Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet 350: 929.
76. Saez-Valero, J., G. Sberna, C.A. McLean & D.H. Small. 1999. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem. 72: 1600-1608.
77. Taniguchi, M., Y. Okayama, Y. Hashimoto, et al. 2008. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 26: 117-122.
78. Halim, A., G. Brinkmalm, U. Ruetschi, et al. 2011. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc. Natl. Acad. Sci. U. S. A. 108: 11848-11853.
79. Hollingworth, P., D. Harold, R. Sims, et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43: 429-435.
80. Naj, A.C., G. Jun, G.W. Beecham, et al. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43: 436-441.
81. Crocker, P.R., J.C. Paulson & A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266.
82. Varki, A. & T. Angata. 2006. Siglecs-the major subfamily of I-type lectins. Glycobiology 16: 1R-27R.
83. Lajaunias, F., J.M. Dayer & C. Chizzolini. 2005. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur. J. Immunol. 35: 243-251.
84. Rabe, K.F., S. Hurd, A. Anzueto, et al. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176: 532-555.
85. World Health Organization. 2008. World Health Statistics 2008. WHO Press. Geneva.
86. Barnes, P.J. 2000. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343: 269-280.
87. Sethi, S. & T.F. Murphy. 2008. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359: 2355-2365.
88. Fukuchi, Y., M. Nishimura, M. Ichinose, et al. 2004. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 9: 458-465.
89. Wang, X., S. Inoue, J. Gu, et al. 2005. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 102: 15791-15796.
90. Yamada, M., T. Ishii, S. Ikeda, et al. 2011. Association of fucosyltransferase 8 (FUT8) polymorphism Thr267Lys with pulmonary emphysema. J. Hum. Genet. 56: 857-860.
91. Sin, D.D., R. Leung, W.Q. Gan & S.P. Man. 2007. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm. Med. 7: 13.
92. More, J.M., D.R. Voelker, L.J. Silveira, et al. 2010. Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease. BMC Pulm. Med. 10: 53.
93. Winkler, C., E.N. Atochina-Vasserman, O. Holz, et al. 2011. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir. Res. 12: 29.
94. Neelamegham, S. & G. Liu. 2011. Systems glycobiology: biochemical reaction networks regulating glycan structure and function. Glycobiology 21: 1541-1553.
95. Katayama, T., K. Arakawa, M. Nakao, et al. 2010. The DBCLS BioHackathon: standardization and interoperability for bioinformatics web services and workflows. The DBCLS BioHackathon Consortium*. J. Biomed. Semantics 1: 8.
96. Comelli, E.M., M. Amado, S.R. Head & J.C. Paulson. 2002. Custom microarray for glycobiologists: considerations for glycosyltransferase gene expression profiling. Biochem. Soc. Symp. 69: 135-142.
97. Comelli, E.M., S.R. Head, T. Gilmartin, et al. 2006. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology 16: 117-131.
98. Yamamoto, H., H. Takematsu, R. Fujinawa, et al. 2007. Correlation index-based responsible-enzyme gene screening (CIRES), a novel DNA microarray-based method for enzyme gene involved in glycan biosynthesis. PLoS One 2: e1232.
99. Nairn, A.V., W.S. York, K. Harris, et al. 2008. Regulation of glycan structures in animal tissues: transcript profiling of glycan-related genes. J. Biol. Chem. 283: 17298-17313.
100. Kizuka, Y., S. Kitazume, M. Yoshida & N. Taniguchi. 2011. Brain-specific expression of N-acetylglucosaminyltransferase IX (GnT-IX) is regulated by epigenetic histone modifications. J. Biol. Chem. 286: 31875-31884.
101. Nakajima, K., S. Kitazume, T. Angata, et al. 2010. Simultaneous determination of nucleotide sugars with ion-pair reversed-phase HPLC. Glycobiology 20: 865-871.
102. Gutman, S. & L.G. Kessler. 2006. The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer 6: 565-571.
103. Cummings, R.D. & M.E. Etzler. 2009. Antibodies and lectins in glycan analysis. In Essentials of Glycobiology. Chapter 45. 2nd ed. A. Varki, et al., Eds.: 633-647. Cold Spring Harbor Laboratory Press. New York.
104. Schoonbroodt, S., M. Steukers, M. Viswanathan, et al. 2008. Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates. J. Immunol. 181: 6213-6221.
105. Yim, M., T. Ono & T. Irimura. 2001. Mutated plant lectin library useful to identify different cells. Proc. Natl. Acad. Sci. U. S. A. 98: 2222-2225.
106. Yabe, R., Y. Itakura, S. Nakamura-Tsuruta, et al. 2009. Engineering a versatile tandem repeat-type alpha2-6sialic acid-binding lectin. Biochem. Biophys. Res. Commun. 384: 204-209.
107. Korekane, H., T. Hasegawa, A. Matsumoto, et al. 2012. Development of an antibody-lectin enzyme immunoassay for fucosylated alpha-fetoprotein. Biochim. Biophys. Acta. In press.